Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology.

‘Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology’ recently published in European Heart Journal 1 rightly dedicates space to the pitfalls that can be encountered when reading presentation ECGs. However, we wish to draw attention to what we think is an important omission. No reference is made in this context to acute aortic syndrome (AAS)—a condition in …

[1]  William Wijns,et al.  [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[2]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[3]  R. Fattori,et al.  Frequency, determinants, and clinical relevance of acute coronary syndrome-like electrocardiographic findings in patients with acute aortic syndrome. , 2007, The American journal of cardiology.

[4]  R. Califf,et al.  Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. , 2007, European heart journal.

[5]  A. Skene,et al.  Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. , 2007, JAMA.

[6]  Jean-Claude Tardif,et al.  Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.

[7]  J. Tijssen,et al.  Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study , 2007, The Lancet.

[8]  W. Maisel.  Unanswered questions--drug-eluting stents and the risk of late thrombosis. , 2007, The New England journal of medicine.

[9]  A. Farb,et al.  Stent thrombosis redux--the FDA perspective. , 2007, The New England journal of medicine.

[10]  J. Ware,et al.  Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. , 2007, JAMA.

[11]  C. Grines,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Journal of the American College of Cardiology.

[12]  G. Maurer,et al.  Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. , 2007, American heart journal.

[13]  David B Matchar,et al.  Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.

[14]  P. Fitzgerald,et al.  Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial , 2006, Circulation.

[15]  Peter Lindgren,et al.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .

[16]  F. Van de Werf,et al.  Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE) , 2005, Heart.

[17]  John B. Wong,et al.  Detecting acute cardiac ischemia in the emergency department , 1990, Journal of General Internal Medicine.

[18]  Rossella Fattori,et al.  Simple risk models to predict surgical mortality in acute type A aortic dissection: the International Registry of Acute Aortic Dissection score. , 2007, The Annals of thoracic surgery.

[19]  S. Kaul,et al.  Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. , 2007, Progress in cardiovascular diseases.

[20]  Anthony A Bavry,et al.  Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. , 2006, The American journal of medicine.

[21]  G. Schuler,et al.  Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment. , 2006, European heart journal.

[22]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[23]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[24]  J. Muller,et al.  Triggering of Acute Cardiovascular Disease and Potential Preventive Strategies , 2006, Circulation.

[25]  K. Eagle,et al.  Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) , 2006, BMJ : British Medical Journal.

[26]  R. Califf,et al.  Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. , 2006, Archives of internal medicine.

[27]  Deepak L. Bhatt,et al.  Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. , 2006, Journal of the American College of Cardiology.

[28]  C. Samama,et al.  Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. , 2006, British journal of anaesthesia.

[29]  Harald Langer,et al.  Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. , 2006, European heart journal.

[30]  Harlan M Krumholz,et al.  Impact of medication therapy discontinuation on mortality after myocardial infarction. , 2006, Archives of internal medicine.

[31]  T. Villines,et al.  The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.

[32]  A. Garg,et al.  Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. , 2006, JAMA.

[33]  R. Califf,et al.  Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. , 2006, Journal of the American College of Cardiology.

[34]  L. Wallentin,et al.  5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study , 2006, The Lancet.

[35]  S. Steinhubl,et al.  Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. , 2006, The New England journal of medicine.

[36]  G. Montalescot,et al.  A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. , 2006, Journal of the American College of Cardiology.

[37]  S. Yusuf,et al.  Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function? , 2006, European heart journal.

[38]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[39]  S. Yusuf,et al.  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.

[40]  A. Yan,et al.  ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. , 2006, American heart journal.

[41]  P. Serruys,et al.  Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis. , 2006, European heart journal.

[42]  I. Scott,et al.  Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era. , 2006, The Cochrane database of systematic reviews.

[43]  R. Bugiardini,et al.  Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. , 2006, Archives of internal medicine.

[44]  A. Gitt,et al.  Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice. , 2006, The American journal of cardiology.

[45]  E. Lonn,et al.  Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. , 2006, European heart journal.

[46]  F. Veglia,et al.  N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty , 2006 .

[47]  Fondaparinux versus enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[48]  L. Køber,et al.  Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction , 2006, Circulation.

[49]  M. Tonelli,et al.  Prophylaxis strategies for contrast-induced nephropathy. , 2006, JAMA.

[50]  Eric Peterson,et al.  Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. , 2006, Journal of the American College of Cardiology.

[51]  C. Rogers,et al.  Devices for distal protection during percutaneous coronary revascularization. , 2006, Circulation.

[52]  G. Mancia,et al.  Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. , 2006, European heart journal.

[53]  Simon Day,et al.  An introductory note to CHMP guidelines: choice of the non‐inferiority margin and data monitoring committees , 2006, Statistics in medicine.

[54]  B. Chaitman.  Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. , 2006, Circulation.

[55]  C. Schindler,et al.  Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. , 2006, Archives of internal medicine.

[56]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[57]  P. Serruys,et al.  Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radio frequency data analysis, is related to clinical presentation. , 2006, American heart journal.

[58]  G. Kelley,et al.  Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. , 2006, Journal of cardiopulmonary rehabilitation.

[59]  J. Borer.  Therapeutic effects of I(f) blockade: evidence and perspective. , 2006, Pharmacological research.

[60]  B. Hemmelgarn,et al.  Refined characterization of the association between kidney function and mortality in patients undergoing cardiac catheterization. , 2006, European heart journal.

[61]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[62]  Shein-Chung Chow,et al.  On non‐inferiority margin and statistical tests in active control trials , 2006, Statistics in medicine.

[63]  P. Steg,et al.  Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. , 2006, Archives of internal medicine.

[64]  A. Kastrati,et al.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.

[65]  V. Durkalski,et al.  Evaluation of Treatment with Direct Thrombin Inhibitors in Patients with Heparin‐Induced Thrombocytopenia , 2006, Pharmacotherapy.

[66]  C. Hamm,et al.  Release pattern of N–terminal pro B–type natriuretic peptide (NT–proBNP) in acute coronary syndromes , 2006, Clinical Research in Cardiology.

[67]  G. Biondi-Zoccai,et al.  Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. , 2006, European heart journal.

[68]  L. Newby,et al.  Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). , 2006, The American journal of cardiology.

[69]  F Xavier Pi-Sunyer,et al.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.

[70]  M. Braun,et al.  Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. , 2006, JAMA.

[71]  S. Mehta,et al.  A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. , 2006, American heart journal.

[72]  K. Alexander,et al.  Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.

[73]  S. Yusuf,et al.  Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. , 2005, American heart journal.

[74]  J. Gore,et al.  Bleeding complications in patients with anemia and acute myocardial infarction. , 2005, American Journal of Cardiology.

[75]  A. Kastrati,et al.  Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.

[76]  F. Van de Werf,et al.  Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. , 2005, European heart journal.

[77]  R. Califf,et al.  Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.

[78]  L. Wallentin,et al.  Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes. Data from the Euro Heart Survey ACS , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[79]  Mary Cushman,et al.  A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. , 2005, Archives of internal medicine.

[80]  K. Alexander,et al.  Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. , 2005, Journal of the American College of Cardiology.

[81]  J. Tijssen,et al.  Early invasive versus selectively invasive management for acute coronary syndromes. , 2005, The New England journal of medicine.

[82]  P. Poole‐Wilson,et al.  5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial , 2005, The Lancet.

[83]  Wei Dong,et al.  Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. , 2005, The American journal of cardiology.

[84]  D. Levy,et al.  Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study , 2005, Circulation.

[85]  Randall C. Thompson,et al.  Relation of anemia at discharge to survival after acute coronary syndromes. , 2005, The American journal of cardiology.

[86]  H. Boshuizen,et al.  Effect Size Estimates of Lifestyle and Dietary Changes on All-Cause Mortality in Coronary Artery Disease Patients: A Systematic Review , 2005, Circulation.

[87]  K. Eagle,et al.  Medication performance measures and mortality following acute coronary syndromes. , 2005, The American journal of medicine.

[88]  B. Gersh,et al.  One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. , 2005, The Journal of thoracic and cardiovascular surgery.

[89]  A. Parkhomenko,et al.  Recommendations for the structure, organization, and operation of intensive cardiac care units. , 2005, European heart journal.

[90]  A. Siegbahn,et al.  FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease , 2005, Heart.

[91]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[92]  R. Califf,et al.  The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndro , 2005, American heart journal.

[93]  K. Eagle,et al.  Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. , 2005, European heart journal.

[94]  E. Boersma,et al.  Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. , 2005, European heart journal.

[95]  D. Siscovick,et al.  Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.

[96]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[97]  Carlos Aguiar,et al.  TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. , 2005, European heart journal.

[98]  C. Terkelsen,et al.  Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. , 2005, European heart journal.

[99]  R. Giugliano,et al.  Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes , 2005, Circulation.

[100]  V. Pasceri,et al.  Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study* , 2005, Circulation.

[101]  J. Diodati,et al.  Resistance to clopidogrel: a review of the evidence. , 2005, Journal of the American College of Cardiology.

[102]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[103]  B. Psaty,et al.  Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. , 2005, JAMA.

[104]  L. Pilote,et al.  Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. , 2005, Archives of internal medicine.

[105]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[106]  M. Laakso,et al.  Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity , 2005 .

[107]  L. Newby,et al.  Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes. , 2005, Annals of emergency medicine.

[108]  Antonio Colombo,et al.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. , 2005, European heart journal.

[109]  S. Yusuf,et al.  Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial , 2005, Circulation.

[110]  L. Newby,et al.  Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/Ameri , 2005, Journal of the American College of Cardiology.

[111]  P. Serruys,et al.  Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. , 2005, Journal of the American College of Cardiology.

[112]  ACE inhibition in stable coronary artery disease. , 2005, The New England journal of medicine.

[113]  W. Gibler,et al.  Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. , 2005, American heart journal.

[114]  F. Wuyts,et al.  Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. , 2005, European heart journal.

[115]  P. Steg,et al.  Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. , 2005, The American journal of cardiology.

[116]  Jeroen J. Bax,et al.  Cardiac multidetector-row computed tomography in patients with unstable angina. , 2005, The American journal of cardiology.

[117]  Sue-Jane Wang,et al.  A Regulatory Perspective on Choice of Margin and Statistical Inference Issue in Non‐inferiority Trials , 2005, Biometrical journal. Biometrische Zeitschrift.

[118]  E. Antman,et al.  Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E , 2005, American heart journal.

[119]  R. Bugiardini.  Normal Coronary Arteries: Clinical Implications and Further Classification , 2005, Herz Kardiovaskuläre Erkrankungen.

[120]  Peter Kearney,et al.  The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. , 2005, European heart journal.

[121]  C Noel Bairey Merz,et al.  Angina with "normal" coronary arteries. , 2005 .

[122]  Á. Avezum,et al.  Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study , 2005, BMJ : British Medical Journal.

[123]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[124]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[125]  Á. Avezum,et al.  Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). , 2005, American heart journal.

[126]  Charles Marc Samama,et al.  Perioperative platelet transfusion: recommendations of the Agence française de sécurité sanitaire des produits de santé (AFSSaPS) 2003 , 2005, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[127]  L. Wallentin,et al.  Hospital therapy traditions influence long-term survival in patients with acute myocardial infarction. , 2005, American heart journal.

[128]  J. Kelton,et al.  Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. , 2005, Blood.

[129]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .

[130]  R. Harrington.  Antithrombotic therapy during percutaneous coronary intervention , 2005, Journal of Thrombosis and Thrombolysis.

[131]  Raghava R. Gollapudi,et al.  Aspirin sensitivity: implications for patients with coronary artery disease. , 2004, JAMA.

[132]  R. Hubbard,et al.  Risk of myocardial infarction and stroke after acute infection or vaccination. , 2004, The New England journal of medicine.

[133]  S. Solomon,et al.  Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction: The Survival And Ventricular Enlargement (SAVE) Study , 2004, Circulation.

[134]  A. Kastrati,et al.  Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel , 2004, Circulation.

[135]  A. Lerman,et al.  Systematic Review: Transient Left Ventricular Apical Ballooning: A Syndrome That Mimics ST-Segment Elevation Myocardial Infarction , 2004, Annals of Internal Medicine.

[136]  S. Steinhubl,et al.  Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. , 2004, Journal of the American College of Cardiology.

[137]  H. White,et al.  N-Terminal Pro–B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes , 2004, Circulation.

[138]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[139]  Deepak L. Bhatt,et al.  Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative , 2004 .

[140]  T. Fehr,et al.  Contrast nephropathy: review focusing on prevention. , 2004, Journal of the American College of Cardiology.

[141]  G. Finet,et al.  Evolution of Spontaneous Atherosclerotic Plaque Rupture With Medical Therapy: Long-Term Follow-Up With Intravascular Ultrasound , 2004, Circulation.

[142]  L. Stitt,et al.  Does clopidogrel increase blood loss following coronary artery bypass surgery? , 2004, The Annals of thoracic surgery.

[143]  H. White,et al.  Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. , 2004, American heart journal.

[144]  V. Boyko,et al.  The Outcome of Coronary Artery Bypass Grafting Surgery among Patients Hospitalized with Acute Coronary Syndrome: The Euro Heart Survey of Acute Coronary Syndrome Experience , 2004, Cardiology.

[145]  Roberto Ferrari,et al.  The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.

[146]  J. Gore,et al.  Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. , 2004, Archives of internal medicine.

[147]  Patrick W Serruys,et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.

[148]  J. Golmard,et al.  Impact of Prior Use or Recent Withdrawal of Oral Antiplatelet Agents on Acute Coronary Syndromes , 2004, Circulation.

[149]  L. Hansson,et al.  Cystatin C: A Novel Predictor of Outcome in Suspected or Confirmed Non–ST-Elevation Acute Coronary Syndrome , 2004, Circulation.

[150]  R. Gupta,et al.  The renal patient with coronary artery disease: current concepts and dilemmas. , 2004, Journal of the American College of Cardiology.

[151]  G. Stone,et al.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. , 2004, Journal of the American College of Cardiology.

[152]  Sunil V. Rao,et al.  Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.

[153]  S. Fichtlscherer,et al.  Prognostic Value of Systemic Endothelial Dysfunction in Patients With Acute Coronary Syndromes: Further Evidence for the Existence of the “Vulnerable” Patient , 2004, Circulation.

[154]  B. Hemmelgarn,et al.  Survival After Coronary Revascularization Among Patients With Kidney Disease , 2004, Circulation.

[155]  M. Pfeffer,et al.  Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. , 2004, European heart journal.

[156]  B. Lindahl,et al.  Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. , 2004, American heart journal.

[157]  Robert M Califf,et al.  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.

[158]  T. Hostetter.  Chronic kidney disease predicts cardiovascular disease. , 2004, The New England journal of medicine.

[159]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[160]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[161]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[162]  S. Yusuf,et al.  Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.

[163]  G. Guyatt,et al.  Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[164]  J. Hirsh,et al.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[165]  E. Ohman,et al.  Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[166]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[167]  C. Cannon.  Revascularisation for everyone? , 2004, European Heart Journal.

[168]  A. D. Cunningham,et al.  Post-traumatic focal true left ventricular aneurysm , 2004, Heart.

[169]  E. Topol,et al.  Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. , 2004, JAMA.

[170]  J. J. Griffin,et al.  Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. , 2004, Journal of the American College of Cardiology.

[171]  Samin K. Sharma,et al.  Anemia is an independent predictor of mortality after percutaneous coronary intervention. , 2004, Journal of the American College of Cardiology.

[172]  E. Braunwald,et al.  The Effect of Routine, Early Invasive Management on Outcome for Elderly Patients with NonST-Segment Elevation Acute Coronary Syndromes , 2004, Annals of Internal Medicine.

[173]  David Brieger,et al.  Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. , 2004, Chest.

[174]  J. Kaski,et al.  Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes , 2004, Heart.

[175]  J. Gore,et al.  Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. , 2004, Archives of internal medicine.

[176]  V. Hasselblad,et al.  Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. , 2004, JAMA.

[177]  R. Ferrari,et al.  The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. , 2004, Journal of the American College of Cardiology.

[178]  R. Califf,et al.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. , 2004, JAMA.

[179]  V. Hasselblad,et al.  Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. , 2004, JAMA.

[180]  V. Kalaria,et al.  Approach to “Aspirin Allergy” in Cardiovascular Patients , 2004, Circulation.

[181]  G. Heusch.  Coronary microembolization*1 , 2004 .

[182]  I. Meredith,et al.  Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. , 2004, American heart journal.

[183]  R. Redberg,et al.  Acute coronary syndromes in women: Is treatment different? should it be? , 2004, Current cardiology reports.

[184]  H. Hod,et al.  Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.

[185]  G. Assmann,et al.  Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C* , 2004, Current medical research and opinion.

[186]  F. Van de Werf,et al.  A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. , 2004, Journal of the American College of Cardiology.

[187]  T. Heer,et al.  Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry). , 2004, The American journal of cardiology.

[188]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry , 2004 .

[189]  E. Topol,et al.  Thrombocytopenia Caused by Abciximab or Tirofiban and Its Association With Clinical Outcome in Patients Undergoing Coronary Stenting , 2004, Circulation.

[190]  David J Cohen,et al.  Stent Thrombosis After Successful Sirolimus-Eluting Stent Implantation , 2004, Circulation.

[191]  J. Rumsfeld,et al.  Renal insufficiency and mortality from acute coronary syndromes. , 2004, American heart journal.

[192]  E. Antman,et al.  Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. , 2004, The American journal of cardiology.

[193]  S. Behar,et al.  Sex, age, and clinical presentation of acute coronary syndromes. , 2004, European heart journal.

[194]  M. Gheorghiade,et al.  Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. , 2004, The American journal of medicine.

[195]  K. Eagle,et al.  Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes , 2004, Circulation.

[196]  K. Kochanek,et al.  Deaths: preliminary data for 2002. , 2004, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[197]  V. Hasselblad,et al.  Differential Treatment Benefit of Platelet Glycoprotein IIb/IIIa Inhibition With Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes: Exploration of Methods , 2004, Circulation.

[198]  R. Gliklich,et al.  Get With the Guidelines for Cardiovascular Secondary Prevention , 2004 .

[199]  E. Antman,et al.  Enoxaparin in Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Treatment Benefits in Prespecified Subgroups , 2001, Journal of Thrombosis and Thrombolysis.

[200]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[201]  G. FitzGerald,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[202]  M. Simoons,et al.  Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. , 2004, American heart journal.

[203]  K. Swedberg,et al.  Buccal versus intravenous nitroglyerin in unstable angina pectoris , 2004, European Journal of Clinical Pharmacology.

[204]  Á. Avezum,et al.  Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). , 2003, American heart journal.

[205]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[206]  Alan Barkun,et al.  Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding , 2003, Annals of Internal Medicine.

[207]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[208]  W. Weintraub,et al.  Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. , 2003, Journal of the American Society of Nephrology : JASN.

[209]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[210]  Á. Avezum,et al.  Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.

[211]  E. Topol,et al.  Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.

[212]  S. Yusuf,et al.  Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study , 2003, Circulation.

[213]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[214]  Deepak L. Bhatt,et al.  Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival , 2003 .

[215]  Werner Klein,et al.  Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) , 2003 .

[216]  E. Antman,et al.  Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. , 2003, American heart journal.

[217]  V. Tapson,et al.  The Evaluation of Suspected Pulmonary Embolism , 2003 .

[218]  A. Kastrati,et al.  Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[219]  C. Heeschen,et al.  Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.

[220]  V. Hasselblad,et al.  Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. , 2003, The American journal of cardiology.

[221]  J. Michael Gaziano,et al.  Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs , 2003, Circulation.

[222]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[223]  P. Libby,et al.  Soluble CD40L: Risk Prediction After Acute Coronary Syndromes , 2003, Circulation.

[224]  Pamela S Douglas,et al.  Acc/aha/ase 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article a Report of the American College of Cardiology/american Heart Association Task Force on Practice Guidelines (acc/aha/ase Committee to Update the 1997 Guidelines for the Clinical Application of Echocar , 2003 .

[225]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[226]  S. Steinhubl,et al.  Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial , 2003, Circulation.

[227]  J. Gore,et al.  Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE) , 2003, Heart.

[228]  J. Tijssen,et al.  C-reactive protein and coronary events following percutaneous coronary angioplasty , 2003 .

[229]  C. Patrono.  Aspirin resistance: definition, mechanisms and clinical read‐outs , 2003, Journal of thrombosis and haemostasis : JTH.

[230]  J. Gore,et al.  From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). , 2003, European heart journal.

[231]  R. Califf,et al.  Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease , 2003, Circulation.

[232]  R. Califf,et al.  N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy , 2003, Circulation.

[233]  C. Herzog,et al.  Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. , 2003, JAMA.

[234]  P. Berger,et al.  Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. , 2003, Journal of the American College of Cardiology.

[235]  P. Gandhi,et al.  Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents , 2003, Current cardiology reports.

[236]  V. Boyko,et al.  Cardiac biomarkers and acute coronary syndromes--the Euro Heart Survey of Acute Coronary Syndromes Experience. , 2003, European heart journal.

[237]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[238]  V. Boyko,et al.  Effect of gender on outcomes of acute coronary syndromes. , 2003, The American journal of cardiology.

[239]  P. Serruys,et al.  Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. , 2003, Journal of the American College of Cardiology.

[240]  K. Malmberg,et al.  Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. , 2003, European heart journal.

[241]  T. Warkentin.  Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. , 2003, Thrombosis research.

[242]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[243]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[244]  Manfred S. Green,et al.  A prospective national survey of management and clinical outcome of acute myocardial infarction in Israel, 2000. , 2003, The Israel Medical Association journal : IMAJ.

[245]  V. Boyko,et al.  Acute coronary syndromes in patients with pre-existing moderate to severe valvular disease of the heart: lessons from the Euro-Heart Survey of acute coronary syndromes. , 2003, European heart journal.

[246]  C. Heeschen,et al.  Soluble CD40 ligand in acute coronary syndromes. , 2003, The New England journal of medicine.

[247]  G. Wagner,et al.  Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. , 2003, Journal of the American College of Cardiology.

[248]  B. Gersh,et al.  Clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting. Implications for mechanical plaque sealing. , 2003, European heart journal.

[249]  S. Yusuf,et al.  Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes , 2003, Circulation.

[250]  J. Tijssen,et al.  Prognostic value of predischarge dobutamine stress echocardiography in chest pain patients with a negative cardiac troponin T. , 2003, Journal of the American College of Cardiology.

[251]  E. Topol,et al.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.

[252]  T. Macdonald,et al.  Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.

[253]  Anthony H. Aletras,et al.  Detecting Acute Coronary Syndrome in the Emergency Department With Cardiac Magnetic Resonance Imaging , 2003, Circulation.

[254]  P. Armstrong,et al.  Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide , 2003 .

[255]  Paul W Armstrong,et al.  Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure , 2003, Circulation.

[256]  L. Lund,et al.  Hemodilution Is Common in Patients With Advanced Heart Failure , 2003, Circulation.

[257]  V. Boyko,et al.  Frequency, characteristics, and outcome of patients hospitalized with acute coronary syndromes with undetermined electrocardiographic patterns. , 2003, The American journal of cardiology.

[258]  Kurex Sidik.  Exact unconditional tests for testing non‐inferiority in matched‐pairs design , 2002, Statistics in medicine.

[259]  E. Falk,et al.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 2003, European heart journal.

[260]  N. Roubinian,et al.  Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. , 2016, The Cochrane database of systematic reviews.

[261]  E. Braunwald,et al.  Benefit of an early invasive management strategy in women with acute coronary syndromes. , 2002, JAMA.

[262]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[263]  L. Wallentin,et al.  A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. , 2002, Journal of the American College of Cardiology.

[264]  R. Hendel,et al.  Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. , 2002, JAMA.

[265]  Fred S Apple,et al.  Predictive Value of Cardiac Troponin I and T for Subsequent Death in End-Stage Renal Disease , 2002, Circulation.

[266]  E. Braunwald,et al.  Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). , 2002, The American journal of cardiology.

[267]  D. Eterović,et al.  Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors. , 2002, American heart journal.

[268]  R. Califf,et al.  Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). , 2002, American heart journal.

[269]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.

[270]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[271]  Jerome Sacks,et al.  Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. , 2002, Journal of the American College of Cardiology.

[272]  Robert H Christenson,et al.  Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. , 2002, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[273]  R. Califf,et al.  Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. , 2002, European heart journal.

[274]  Alan C. Wilson,et al.  Effect of anemia on 1-year mortality in patients with acute myocardial infarction. , 2002, American heart journal.

[275]  H. Arnesen,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[276]  S. Yusuf,et al.  Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups , 2002, Circulation.

[277]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[278]  K. Fox,et al.  Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial , 2002, The Lancet.

[279]  H. White,et al.  Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study☆☆☆★ , 2002 .

[280]  Deepak L. Bhatt,et al.  Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. , 2002, European heart journal.

[281]  Peter Libby,et al.  Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis , 2002, Circulation research.

[282]  R. Califf,et al.  Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes , 2002, Circulation.

[283]  G Finet,et al.  Multiple Atherosclerotic Plaque Rupture in Acute Coronary Syndrome: A Three-Vessel Intravascular Ultrasound Study , 2002, Circulation.

[284]  B. Lindahl,et al.  N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. , 2002, Journal of the American College of Cardiology.

[285]  E. Topol,et al.  Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study , 2002, The Lancet.

[286]  E. Funkhouser,et al.  Atypical presentations among Medicare beneficiaries with unstable angina pectoris. , 2002, The American journal of cardiology.

[287]  M. Kayıkçıoğlu,et al.  Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty. , 2002, Acta cardiologica.

[288]  M L Simoons,et al.  A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). , 2002, European heart journal.

[289]  W Klein,et al.  Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). , 2002, European heart journal.

[290]  J. Stamler,et al.  Nitric oxide in the human respiratory cycle , 2002, Nature Medicine.

[291]  R. Califf,et al.  Sustained Ventricular Arrhythmias Among Patients With Acute Coronary Syndromes With No ST-Segment Elevation: Incidence, Predictors, and Outcomes , 2002, Circulation.

[292]  A. Greinacher,et al.  Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. , 2002, Chest.

[293]  F. Neumann,et al.  Women do have an improved long-term outcome after non-ST-elevation acute coronary syndromes treated very early and predominantly with percutaneous coronary intervention: a prospective study in 1,450 consecutive patients. , 2002, Journal of the American College of Cardiology.

[294]  C. Zoccali,et al.  Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[295]  R. Califf,et al.  Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. , 2002, The New England journal of medicine.

[296]  L. Wallentin,et al.  Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study , 2002, The Lancet.

[297]  C. Patrono,et al.  Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[298]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[299]  L. Wallentin,et al.  The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. , 2002, American heart journal.

[300]  W. Hillis,et al.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial , 2002, The Lancet.

[301]  S. Yusuf,et al.  Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.

[302]  H. White,et al.  Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes , 2002, Circulation.

[303]  Robert Parrish,et al.  Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. , 2002, JAMA.

[304]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[305]  S. Marsch,et al.  Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. , 2002, Archives of internal medicine.

[306]  L. Rice,et al.  Delayed-Onset Heparin-Induced Thrombocytopenia , 2002, Annals of Internal Medicine.

[307]  C. Granger,et al.  Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. , 2002, American heart journal.

[308]  R. Califf,et al.  Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data , 2002, The Lancet.

[309]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[310]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.

[311]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[312]  R. Becker,et al.  Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition. , 2001, American heart journal.

[313]  S. Anand.  Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Eikelboom JW, Hirsh J, Weitz J, Johnston M, Yi Q, Yusuf S. Circulation 2002; 105: 1650- 1655. , 2002 .

[314]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[315]  M. Roe,et al.  Pharmacological Treatment of Elderly Patients with Acute Coronary Syndromes without Persistent ST Segment Elevation , 2002, Drugs & aging.

[316]  L. Wallentin,et al.  Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. , 2002, Journal of the American College of Cardiology.

[317]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[318]  Deepak L. Bhatt,et al.  Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes , 2001, Circulation.

[319]  E. Topol,et al.  Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. , 2001, American heart journal.

[320]  A. Jacobs,et al.  Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). , 2001, Journal of the American College of Cardiology.

[321]  M. Simoons,et al.  Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. , 2001, European heart journal.

[322]  H. Krumholz,et al.  Blood transfusion in elderly patients with acute myocardial infarction. , 2001, The New England journal of medicine.

[323]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[324]  V. Fuster,et al.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.

[325]  V. Fuster,et al.  AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Journal of the American College of Cardiology.

[326]  J. Pell,et al.  Gender and survival: a population-based study of 201,114 men and women following a first acute myocardial infarction. , 2001, Journal of the American College of Cardiology.

[327]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[328]  K. Alexander,et al.  Representation of elderly persons and women in published randomized trials of acute coronary syndromes. , 2001, JAMA.

[329]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[330]  R. Califf,et al.  Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. , 2001, Journal of the American College of Cardiology.

[331]  G. Dagenais,et al.  Biological Profiles in Subjects With Recurrent Acute Coronary Events Compared With Subjects With Long-Standing Stable Angina , 2001, Circulation.

[332]  E. Topol,et al.  Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.

[333]  E. Braunwald,et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.

[334]  V. Hasselblad,et al.  Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy , 2001, Circulation.

[335]  M. Simoons.  Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial , 2001, The Lancet.

[336]  G. Stone,et al.  Creatine kinase-MB fraction elevation after percutaneous coronary intervention in patients with chronic renal failure. , 2001, The American journal of cardiology.

[337]  David P Miller,et al.  Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. , 2001, Journal of the American College of Cardiology.

[338]  J. Gore,et al.  Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. , 2001, Journal of the American College of Cardiology.

[339]  J. Kelton,et al.  Temporal aspects of heparin-induced thrombocytopenia. , 2001, The New England journal of medicine.

[340]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[341]  S. Yusuf,et al.  Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina , 2001 .

[342]  J. Marshall,et al.  Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? , 2001, Critical care medicine.

[343]  Grace Investigators,et al.  Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. , 2001, American heart journal.

[344]  L. Wallentin,et al.  Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.

[345]  A. Greinacher,et al.  Drugs for the Prevention and Treatment of Thrombosis in Patients with Heparin-Induced Thrombocytopenia , 2001, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[346]  R. Sorelle.  Cardiovascular news. VMAC. , 2000, Circulation.

[347]  R. Sorelle.  Cardiovascular news. FLORIDA. , 2000, Circulation.

[348]  Young Jj,et al.  Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. , 2000 .

[349]  G. De Backer,et al.  Recent findings on return to work after an acute myocardial infarction or coronary artery bypass grafting. , 2000, Acta cardiologica.

[350]  K. Eagle,et al.  Quality improvement initiative and its impact on the management of patients with acute myocardial infarction. , 2000, Archives of internal medicine.

[351]  J. W. Box,et al.  Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study , 2000 .

[352]  E J Topol,et al.  A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. , 2000, American heart journal.

[353]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[354]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[355]  Deepak L. Bhatt,et al.  Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. , 2000, Circulation.

[356]  U Keil,et al.  The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. , 2000, European heart journal.

[357]  L. Wallentin,et al.  The combination of a continuous 12-lead ECG and troponin T; a valuable tool for risk stratification during the first 6 hours in patients with chest pain and a non-diagnostic ECG. , 2000, European heart journal.

[358]  J J Chen,et al.  An approximate unconditional test of non-inferiority between two proportions. , 2000, Statistics in medicine.

[359]  C. Patrono,et al.  Oxidant Stress and Aspirin-Insensitive Thromboxane Biosynthesis in Severe Unstable Angina , 2000, Circulation.

[360]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[361]  F. Menapace,et al.  Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. , 2000, American heart journal.

[362]  E. Ellerbeck,et al.  Impact of quality improvement activities on care for acute myocardial infarction. , 2000, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[363]  R. Califf,et al.  Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome , 2000, Journal of the American College of Cardiology.

[364]  E. Braunwald,et al.  A classification of unstable angina revisited. , 2000, Circulation.

[365]  A. Darnell,et al.  Literature Abstracts , 2000, Pediatric Nephrology.

[366]  L. Wallentin,et al.  Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial , 2000, The Lancet.

[367]  E W Steyerberg,et al.  Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. , 2000, Circulation.

[368]  S. Yusuf,et al.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis , 2000, The Lancet.

[369]  R M Whitlock,et al.  Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study , 2000, BMJ : British Medical Journal.

[370]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[371]  W. Boden,et al.  Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial , 2000, The Lancet.

[372]  H. Wolf,et al.  Trends in the incidence of acute myocardial infarction between 1984 and 1993 - The Halifax County MONICA Project. , 2000, The Canadian journal of cardiology.

[373]  C. Heeschen,et al.  Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. , 2000, Journal of the American College of Cardiology.

[374]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[375]  A. Raizner,et al.  Catastrophic outcomes of noncardiac surgery soon after coronary stenting. , 2000, Journal of the American College of Cardiology.

[376]  M. Davies.  The pathophysiology of acute coronary syndromes , 2000, Indian heart journal.

[377]  A Evangelista,et al.  The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. , 2000, JAMA.

[378]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[379]  R. Califf,et al.  Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. , 1999, The American journal of cardiology.

[380]  H. White,et al.  Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban , 1999, The Lancet.

[381]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. , 1999, Circulation.

[382]  J. Maessen,et al.  Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. , 1999, Chest.

[383]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[384]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[385]  L. Wallentin,et al.  Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.

[386]  F. Ragmin.  Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.

[387]  H. White,et al.  Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression. , 1999, The American journal of cardiology.

[388]  F Van de Werf,et al.  Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. , 1999, The New England journal of medicine.

[389]  L. Køber,et al.  Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarction , 1999, The Lancet.

[390]  M. Bates,et al.  Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy , 1999, American journal of hematology.

[391]  G. Plosker,et al.  Trimetazidine , 1999, Drugs.

[392]  W. Gibler,et al.  National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. , 1999, Clinical chemistry.

[393]  A. Remppis,et al.  Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing. , 1999, Clinical chemistry.

[394]  C. Heeschen,et al.  Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. , 1999, The New England journal of medicine.

[395]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[396]  R. Califf,et al.  Prognostic value of the admission electrocardiogram in acute coronary syndromes. , 1999, JAMA.

[397]  G. Wells,et al.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.

[398]  L. Wallentin,et al.  Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999 .

[399]  M. Keltai,et al.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). , 1999, European heart journal.

[400]  A. Siegbahn,et al.  Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. , 1999, Lancet.

[401]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[402]  David P Miller,et al.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. , 1998, Circulation.

[403]  L. Wallentin,et al.  The FRISC experience with troponin T. Use as decision tool and comparison with other prognostic markers. , 1998, European heart journal.

[404]  T D Koepsell,et al.  Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina. , 1998, Journal of the American College of Cardiology.

[405]  L. Goodnough,et al.  Perioperative myocardial ischemic episodes are related to hematocrit level in patients undergoing radical prostatectomy , 1998, Transfusion.

[406]  W. O’Neill,et al.  A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial. , 1998, Journal of the American College of Cardiology.

[407]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[408]  N R Hicks,et al.  Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study , 1998, Heart.

[409]  R. Kleiger,et al.  Correction: Outcomes in Patients with Acute Non-Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy. , 1998, The New England journal of medicine.

[410]  E. Antman,et al.  C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .

[411]  M. Simoons,et al.  Unstable angina: good long-term outcome after a complicated early course. , 1998, Journal of the American College of Cardiology.

[412]  C. Sylvén,et al.  Excellent reliability of nurse-based bedside diagnosis of acute myocardial infarction by rapid dry-strip creatine kinase MB, myoglobin, and troponin T. , 1998, American heart journal.

[413]  D. Kromhout,et al.  The incidence of suspected myocardial infarction in Dutch general practice in the period 1978-1994. , 1998, European heart journal.

[414]  A. Verbruggen,et al.  Effect of Clopidogrel on Naproxen-Induced Gastrointestinal Blood Loss in Healthy Volunteers , 1998, Drug metabolism and drug interactions.

[415]  C. Heeschen,et al.  Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. , 1997, The New England journal of medicine.

[416]  L. Wallentin,et al.  Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC) , 1997 .

[417]  T. Investigators.  Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. , 1997, Circulation.

[418]  U. Losert,et al.  Variable Platelet Response to Low-dose ASA and the Risk of Limb Deterioration in Patients Submitted to Peripheral Arterial Angioplasty , 1997, Thrombosis and Haemostasis.

[419]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .

[420]  W. Pevec,et al.  A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. , 1997, American journal of surgery.

[421]  R. Califf,et al.  Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Compl , 1997, Journal of the American College of Cardiology.

[422]  C. Cannon,et al.  The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. , 1997, Journal of the American College of Cardiology.

[423]  R. Foley,et al.  Cardiac disease in chronic uremia: clinical outcome and risk factors. , 1997, Advances in renal replacement therapy.

[424]  W. Klein,et al.  Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) , 1997, Circulation.

[425]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[426]  K. Malmberg.  Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[427]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[428]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[429]  E. Bramucci,et al.  Tissue-factor antigen and activity in human coronary atherosclerotic plaques , 1997, The Lancet.

[430]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[431]  D Wybenga,et al.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. , 1996, The New England journal of medicine.

[432]  J. Berlin,et al.  Effect of anaemia and cardiovascular disease on surgical mortality and morbidity , 1996, The Lancet.

[433]  Salim Yusuf,et al.  Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials , 1996, BMJ.

[434]  M. Whooley,et al.  Adding Heparin to Aspirin Reduces the Incidence of Myocardial Infarction and Death in Patients With Unstable Angina: A Meta-analysis , 1996 .

[435]  K. Fox,et al.  Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram. , 1996, Heart.

[436]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[437]  K. Wiklund,et al.  Low-molecular-weight heparin during instability in coronary artery disease , 1996 .

[438]  H. Asato,et al.  Electrocardiographic abnormalities in patients with acute aortic dissection. , 1995, The American journal of cardiology.

[439]  J. Kaski,et al.  Rapid angiographic progression of coronary artery disease in patients with angina pectoris. The role of complex stenosis morphology. , 1995, Circulation.

[440]  F. Schiele,et al.  Use of recombinant hirudin as antithrombotic treatment in patients with heparin‐induced thrombocytopenia , 1995, American journal of hematology.

[441]  T. Raghunathan,et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.

[442]  E. Gurfinkel,et al.  Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. , 1995, Journal of the American College of Cardiology.

[443]  J Herlitz,et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.

[444]  P. Bossuyt,et al.  Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. , 1995, Journal of the American College of Cardiology.

[445]  E. Antman,et al.  Evaluation of a rapid bedside assay for detection of serum cardiac troponin T. , 1995, JAMA.

[446]  S. Brister,et al.  Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. , 1995, The Canadian journal of cardiology.

[447]  D. Sackett,et al.  The number needed to treat: a clinically useful measure of treatment effect , 1995, BMJ.

[448]  L. Brace,et al.  Development of Aspirin Resistance in Persons With Previous Ischemic Stroke , 1994, Stroke.

[449]  J. D'Elia,et al.  Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. , 1994, The New England journal of medicine.

[450]  J. Mcmanus.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial: The TIMI IIIB Investigators Circulation 89:1545–1556 Apr 1994 , 1994 .

[451]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[452]  L. Wilkins.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. , 1994, Circulation.

[453]  D. Waters,et al.  Aspirin Versus Heparin to Prevent Myocardial Infarction During the Acute Phase of Unstable Angina , 1993, Circulation.

[454]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[455]  L. Brace,et al.  Platelet Aggregation in Patients With Atrial Fibrillation Taking Aspirin or Warfarin , 1993, Stroke.

[456]  L. Wallentin,et al.  Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease , 1993, Journal of internal medicine.

[457]  L. Fleisher,et al.  Relationship between postoperative anemia and cardiac morbidity in high‐risk vascular patients in the intensive care unit , 1993, Critical care medicine.

[458]  L. Wallentin,et al.  Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group. , 1993, International journal of cardiology.

[459]  K. Lindvall,et al.  Prognostic significance of exercise thallium-201 myocardial perfusion imaging compared to stress echocardiography and clinical variables in patients with unstable angina who respond to medical treatment. , 1993, International journal of cardiology.

[460]  L. Brace,et al.  Aspirin Response and Failure in Cerebral Infarction , 1993, Stroke.

[461]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[462]  J. Hirsh.  Heparin and low-molecular weight heparins , 1992 .

[463]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[464]  R. Weintraub,et al.  Comparison of two transfusion strategies after elective operations for myocardial revascularization. , 1992, The Journal of thoracic and cardiovascular surgery.

[465]  H. Katus,et al.  The prognostic value of serum troponin T in unstable angina. , 1992, The New England journal of medicine.

[466]  K. Lindvall,et al.  Predischarge exercise echocardiography in patients with unstable angina who respond to medical treatment , 1992, Clinical cardiology.

[467]  H G Welch,et al.  Prudent Strategies for Elective Red Blood Cell Transfusion , 1992, Annals of Internal Medicine.

[468]  K. Mizuno,et al.  Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. , 1992, The New England journal of medicine.

[469]  C. Furberg,et al.  Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. , 1991, The American journal of cardiology.

[470]  A. V. van Zanten,et al.  Interferences in current methods for measurements of creatinine. , 1991, Clinical chemistry.

[471]  K. Brown.  Prognostic value of thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment. , 1991, Journal of the American College of Cardiology.

[472]  L. Wallentin,et al.  Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease. , 1991, European heart journal.

[473]  E. Hannisdal,et al.  Prognostic factors in multiple myeloma in a population‐based trial , 1990, European journal of haematology.

[474]  C. Cimminiello,et al.  Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. , 1990, Circulation.

[475]  E. Cook,et al.  Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study). , 1989, The American journal of cardiology.

[476]  C. Furberg,et al.  Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. , 1989, BMJ.

[477]  E. Braunwald,et al.  Unstable angina. A classification. , 1989, Circulation.

[478]  D. Sackett,et al.  One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people. , 1989, The Canadian journal of cardiology.

[479]  W. Dassen,et al.  Angiographic and clinical characteristics of patients with unstable angina showing an ECG pattern indicating critical narrowing of the proximal LAD coronary artery. , 1989, American heart journal.

[480]  K. Turkulin,et al.  Predictive markers of occupational activity in 415 post myocardial infarction patients after one-year follow-up. , 1988, European heart journal.

[481]  P. Théroux,et al.  Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.

[482]  J. Wittes,et al.  Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. , 1988, JAMA.

[483]  K. Schechtman,et al.  Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: results from the Multicenter Diltiazem Reinfarction Study. , 1987, The American journal of cardiology.

[484]  J. Lubsen,et al.  Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). , 1987, The American journal of cardiology.

[485]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.

[486]  S. Scott,et al.  Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study. , 1987, The New England journal of medicine.

[487]  D. Gordon,et al.  High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. , 1986, Circulation.

[488]  L Roy,et al.  Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.

[489]  J. Alpert,et al.  Recent changes in attack and survival rates of acute myocardial infarction (1975 through 1981). The Worcester Heart Attack Study. , 1986, JAMA.

[490]  M. Weisfeldt,et al.  Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. , 1986, The New England journal of medicine.

[491]  A. Maseri,et al.  Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit. , 1986, The American journal of cardiology.

[492]  M. Davies,et al.  Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. , 1986, Circulation.

[493]  E. Falk.  Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. , 1985, Circulation.

[494]  D. Waters,et al.  A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. , 1985, Journal of the American College of Cardiology.

[495]  Johan Herlitz,et al.  Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. , 1985, European heart journal.

[496]  B. Weksler,et al.  Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. , 1985, Stroke.

[497]  M. Lesch,et al.  Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy. , 1983, American Journal of Cardiology.

[498]  J. Heinsimer,et al.  Intravenous Nitroglycerin in the Treatment of Spontaneous Angina Pectoris: A Prospective, Randomized Trial , 1983, Circulation.

[499]  D. Kelly,et al.  Intravenous nitroglycerine in refractory unstable angina pectoris. , 1982, Australian and New Zealand journal of medicine.

[500]  S. Spielman,et al.  Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action. , 1982, Archives of internal medicine.

[501]  M. Bertrand,et al.  Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. , 1982, Circulation.

[502]  A. Telford,et al.  TRIAL OF HEPARIN VERSUS ATENOLOL IN PREVENTION OF MYOCARDIAL INFARCTION IN INTERMEDIATE CORONARY SYNDROME , 1981, The Lancet.

[503]  E. Antman,et al.  Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. , 1980, The New England journal of medicine.

[504]  G. Hutchins,et al.  Coronary artery embolism and myocardial infarction. , 1978, Annals of internal medicine.

[505]  D. Thelle,et al.  THE TROMSØHEART-STUDY HIGH-DENSITY LIPOPROTEIN AND CORONARY HEART-DISEASE: A PROSPECTIVE CASE-CONTROL STUDY , 1977, The Lancet.

[506]  L. Campeau.  Letter: Grading of angina pectoris. , 1976, Circulation.

[507]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[508]  M. Prinzmetal,et al.  Angina pectoris. I. A variant form of angina pectoris; preliminary report. , 1959, The American journal of medicine.